PARTICIPATE IN A RESEARCH STUDY
Need further assistance? Please email info@ranchoresearch.org.
Indication:
Chronic kidney disease
Trial Name:
GKPTN
Description:
Contact:
A Prospective International Multi-Centre, Observational Cohort Study of Incident and Prevalent Patients Diagnosed with a Kidney Disease
(562) 385-7463
Investigator:
Nina Patel, MD
Sponsor:
The George Clinical Institute for Global Health
Funding:
Industry
Indication:
Chronic kidney disease
Trial Name:
ZENITH
Description:
Contact:
A Phase 2b Multicentre, Randomised, Double-Blind, Placebo- Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with an eGFF Between 20 and 60 mL/min/1.73 m2
(562) 385-7463
Investigator:
Nina Patel, MD
Sponsor:
AstraZeneca
Funding:
Industry
Indication:
Chronic kidney disease-related hyperkalemia and metabolic acidosis
Trial Name:
NEUTRALIZE
Description:
Contact:
A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease
(562) 385-7020
Investigator:
Nina Patel, MD
Sponsor:
AstraZeneca
Funding:
Industry
Indication:
Diabetic foot ulcers
Trial Name:
NuShield
Description:
Contact:
A Phase 3, Prospective, Multicenter, Randomized, Controlled Clinical Study of NuShield® and Standard of Care (SOC) Compared to SOC Alone for the Management of Diabetic Foot Ulcers
(562) 385-6201
Investigator:
David Armstrong, DPM
Sponsor:
Organogenesis Inc.
Funding:
Industry
Indication:
Epilepsy
Trial Name:
Illuminate
Description:
Contact:
A Phase 4, Long-Term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated with Epidiolex (Cannabidiol) Oral Solution
(562) 385-7020
Investigator:
Hui Gong, MD
Sponsor:
GW Research LTD
Funding:
Industry
Indication:
Epilepsy
Trial Name:
RAISE
Description:
Contact:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IV Ganaxolone in RSE Patients Who Have Failed Benzodiazepines and Two or More Second Line Intravenous Antiepileptic Drugs (AEDs)
(562) 385-7020
Investigator:
Susan Shaw, MD
Sponsor:
Marinus Pharmacetuticals
Funding:
Industry
Indication:
Polycystic kidney disease
Trial Name:
FALCON
Description:
Contact:
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease
(562) 385-7048
Investigator:
Nina Patel, MD
Sponsor:
Reata Pharmaceuticals
Funding:
Industry
Indication:
Spinal cord injury-related urinary bladder dysfunction and incontinenece
Trial Name:
Bladder Stim
Description:
Contact:
The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life after Acute Traumatic Spinal Cord Injury
(562) 385-6201
Investigator:
David Ginsberg, MD
Sponsor:
University of Utah
Funding:
Industry
Indication:
Stroke rehabilitation
Trial Name:
FitMi Plus
Description:
Contact:
FitMi Plus: Smart Functional Modules for Practicing Activities of Daily Living after Stroke
(562) 385-7463
Investigator:
Susan Shaw, MD
Sponsor:
Flint Rehab
Funding:
Industry
Indication:
Stroke- or TBI-related lower extremity spasticity
Trial Name:
ABOLISH
Description:
Contact:
A Phase 4 International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the effectiveness of ABOBONT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort
(562) 385-7048
Investigator:
Ziyad Ayyoub, MD
Sponsor:
Ipsen
Funding:
Industry
Indication:
Stroke- or TBI-related lower extremity spasticity
Trial Name:
PHLEX-LOW
Description:
Contact:
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of a Single-Dose of MYOBLOC in Adult Subjects with Lower Limb Monoplegia or Hemiplegia Spasticity Due to Stroke or TBI, Followed by an Open-Label Extension Safety Study of Multiple Doses
(562) 385-7048
Investigator:
Ziyad Ayyoub, MD
Sponsor:
Supernus Pharmaceuticals
Funding:
Industry
Indication:
Stroke- or TBI-related upper extremity spasticity
Trial Name:
DIRECTION
Description:
Contact:
A Phase 4 Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity
(562) 385-7048
Investigator:
Ziyad Ayyoub, MD
Sponsor:
Ipsen
Funding:
Industry
Indication:
Stroke- or TBI-related upper extremity spasticity
Trial Name:
PHLEX-UP
Description:
Contact:
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC®
(562) 385-7048
Investigator:
Ziyad Ayyoub, MD
Sponsor:
Supernus Pharmaceuticals
Funding:
Industry
Indication:
Ulcers of the lower extremity
Trial Name:
AnGes
Description:
Contact:
A Phase 2 Double-Blind, Randomized, Placebo-Bontrolled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity
(562) 385-6201
Investigator:
David Armstrong, DPM
Sponsor:
AnGes USA Inc.
Funding:
Industry
Indication:
Users of long-term indwelling catheters
Trial Name:
Silq
Description:
Contact:
A Phase 4, Prospective, Multi-center, Randomized Study to Assess the Ability of the Silq ClearTract Urinary Catherter to Reduce Biofilm Formation When Compared to Two Types of Commercially Available Foley Catheters (Silver-Coated Latex and Silicone-Coated Latex)
(562) 385-6201
Investigator:
Evgeniy Kreydin, MD
Sponsor:
Silq Technologies Corporation
Funding:
Industry